Welcome to LookChem.com Sign In|Join Free

CAS

  • or

148707-39-5

Post Buying Request

148707-39-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Benzoic acid, 3,4,5-tris(acetyloxy)-, (2R,3R)-5,7-bis(acetyloxy)-3,4-dihydro-2-[3,4,5-tris(acetyloxy)phenyl]-2 H-1-benzopyran-3-yl ester 148707-39-5

    Cas No: 148707-39-5

  • No Data

  • 1 Kilogram

  • 10000 Metric Ton/Month

  • Shanghai Upbio Tech Co.,Ltd
  • Contact Supplier

148707-39-5 Usage

General Description

AcEGCG, or acetylated epigallocatechin-3-gallate, is a chemical compound derived from epigallocatechin-3-gallate (EGCG), which is a polyphenol found in green tea. AcEGCG is produced by acetylating EGCG, thereby altering its structure and potentially its biological properties. Studies have shown that AcEGCG possesses antioxidant, anti-inflammatory, and anticancer properties, making it a promising compound for various pharmaceutical and medical applications. Additionally, AcEGCG has been shown to have potential neuroprotective effects, as well as the ability to inhibit the growth of certain cancer cells. Further research is needed to fully understand the mechanisms and potential benefits of AcEGCG.

Check Digit Verification of cas no

The CAS Registry Mumber 148707-39-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,7,0 and 7 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 148707-39:
(8*1)+(7*4)+(6*8)+(5*7)+(4*0)+(3*7)+(2*3)+(1*9)=155
155 % 10 = 5
So 148707-39-5 is a valid CAS Registry Number.

148707-39-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name (-)-epigallocatechin 3-O-galloylperacetate

1.2 Other means of identification

Product number -
Other names (-)-Epigallocatechin gallate peracetate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:148707-39-5 SDS

148707-39-5Relevant articles and documents

(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells

Shin, Sunhye,Kim, Mi Kyoung,Jung, Woong,Chong, Youhoon

, (2018)

Urokinase plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) are established independent biomarkers for high metastasis risk in breast cancer. In this study, we investigated the regulatory activity of (-)-epigallocatechin-3-gallate (EGCG) and its derivatives on uPA and PAI-1 expression and thereby their anti-metastatic potential. EGCG showed only marginal effects on the uPA system and on the metastatic behavior of breast cancer cells (MDA-MB-231). However, the EGCG derivative 3e with a methyl-substituted carbonate substituent at the 4″-position showed potent inhibition of PAI-1 (62%) and uPA (50%) expression. The Ras-extracellular-signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-kinase (PI3K)/Akt/NF-κB pathways, which regulate uPA and PAI-1 expression, were also affected by 3e (25%, 45%, and 25% reduction, respectively). In line with these findings, substantial reduction in metastatic behavior of MDA-MB-231 cells, such as adhesion (40%), invasion (56%), and migration (40%), was observed in the presence of 3e. It is also noteworthy that, in MDA-MB-231 cells, 3e did not exert any beneficial effect on the expression of matric metalloprotein (MMP) 2 and 9, which indicates that the anti-metastatic activity of 3e in MDA-MB-231 cells is not related to its regulation of the expression of MMPs. Taken together, we have shown that the EGCG derivative 3e could suppress the metastatic behavior of MDA-MB-231 cells through regulation of uPA and PAI-1.

FLAVAN-3-OLS AND PROANTHOCYANIDINS FROM CISTUS INCANUS

Petereit, Frank,Kolodziej, Herbert,Nahrstedt, Adolf

, p. 981 - 985 (1991)

Four monomeric and seven oligomeric flavanoids have been identified from a Cistus incanus subspecies traditionally used for treatment of skin diseases in northern parts of Greece and identified as subsp. tauricus.Flavan-3-ols are (+)-catechin, (+)-gallocatechin, the novel (+)-gallocatechin 3-gallate and the rarely occurring (+)-catechin 3-O-α-L-rhamnoside; proanthocyanidins are procyanidins B1 and B3, gallocatechin-(4α->8)-gallocatechin, its novel (4α->6)-regioisomer, gallocatechin-(4α->8)-catechin, the tentatively identified novel catechin-(4α->8)-gallocatechin and the trimer gallocatechin-(4α->8)-gallocatechin-(4α->8)-catechin.The uncommon flavanone 2R,3R-dihydromyricetin was also obtained.

(-)-epigallocatechin gallate prodrugs , preparation method thereof and composition for mitochondrial biosis

-

Paragraph 0169; 0172; 0173, (2019/12/31)

The present invention relates to an epigallocatechin gallate prodrug, a method for manufacturing the same, and a composition for promoting mitochondrial biosynthesis comprising the same. A compound represented by chemical formula (1) according to the present invention increases the activity of PGC-1andalpha;, AMPK, and SIRT1, known as mitochondrial biosynthesis regulators, increases the amount of mitochondrial DNA, and increases a NAD+/NADH ratio, a level of cytochrome c, the synthesis of ATP, and oxygen consumption, thereby confirming an effect of increasing the mitochondrial activity and biosynthesis. In addition, it is confirmed that the compound has an effect of having a high absorption rate and slow metabolism in vivo compared to an existing epigallocatechin gallate, thereby being useful for a purpose of preventing or treating diseases related to mitochondrial dysfunction.COPYRIGHT KIPO 2020

ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

-

Page/Page column 67; 69, (2019/12/28)

Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 148707-39-5